Newron Pharmaceuticals SpA, a biopharmaceutical entity dedicated to innovating therapies for central and peripheral nervous system disorders, has announced a significant financial boost. The company has entered into a subscription agreement with a consortium of existing and new shareholders from Europe and Asia, enabling proceeds of up to EUR 38 million. This infusion of capital is crucial for advancing its pivotal ENIGMA-TRS phase III program.
Investment Details
The agreement allows the investor group to acquire up to 779,624 newly issued shares at a subscription price of EUR 19.24 per share, generating initial gross proceeds of up to EUR 15 million. As the ENIGMA-TRS 1 and 2 pivotal studies progress towards their anticipated 12-week results—expected by late 2026—the group will have the opportunity to purchase additional shares for total proceeds of EUR 11 million, determined by a pre-established formula.
Furthermore, contingent upon positive results from the ENIGMA-TRS studies, the investor group may subscribe to additional shares for total proceeds of EUR 12 million. This structured approach not only solidifies Newron’s financial foundation but also aligns the investors’ interests with the successful outcomes of ongoing research.
Strategic Validation
Roberto Galli, CFO of Newron, remarked on the investment, emphasizing its role as a validation of the company’s strategy for evenamide. This potential first add-on therapy for schizophrenia aims to provide a new treatment avenue for patients who struggle with existing options. Galli noted that the financing will extend operational capabilities beyond the upcoming pivotal study results, allowing the company to maintain momentum in its phase III development.
Listing and Trading
The newly issued shares are expected to be listed and traded on the SIX Swiss Exchange shortly, under the same ISIN as existing shares. Additionally, these shares will also be available on the Primärmarkt of the Düsseldorf Stock Exchange and the Quotation Board of the Frankfurt Stock Exchange (Xetra). This broadening of trading options enhances Newron’s visibility and accessibility to investors.
Overview of ENIGMA-TRS Studies
The ENIGMA-TRS pivotal phase III program comprises two key studies: ENIGMA-TRS 1 and ENIGMA-TRS 2. ENIGMA-TRS 1, initiated in August 2025, involves a one-year, international, double-blind, placebo-controlled trial enrolling at least 600 patients. This study aims to assess the efficacy, safety, and tolerability of evenamide administered at 15 mg and 30 mg twice daily as an adjunct therapy to current antipsychotics, including clozapine.
In parallel, ENIGMA-TRS 2, launched in December 2025, is a 12-week, randomized, double-blind, placebo-controlled trial. This study will evaluate the same dosage of evenamide in a cohort of at least 400 patients with treatment-resistant schizophrenia. These rigorous clinical trials are designed to provide robust data on the potential benefits of evenamide.
Unique Mechanism of Action
Evenamide stands out as a novel, orally administered compound with a distinct mechanism of action. It selectively blocks voltage-gated sodium channels (VGSCs) without interfering with more than 130 other CNS targets. This specificity allows evenamide to normalize glutamate release triggered by abnormal sodium channel activity, without altering basal glutamate levels.
Research has shown that combining subtherapeutic doses of evenamide with other antipsychotics, including clozapine, can yield synergistic effects. These combinations demonstrated beneficial outcomes in animal models of psychosis, indicating the potential for evenamide to enhance treatment efficacy for patients inadequately responding to existing therapies.
Lasting Benefits
The long-term effects observed in clinical studies suggest that the benefits of evenamide may persist even after the drug is metabolized. This characteristic provides hope for patients with schizophrenia who have not found relief with current treatments. By addressing the unmet needs of this population, evenamide represents a pioneering approach in the landscape of psychiatric medications.
Looking Ahead
As Newron moves forward with its ENIGMA-TRS phase III program, the financial backing from this latest investment will play a critical role in the continuation of its research and development endeavors. The positive trajectory of evenamide could potentially reshape the treatment paradigm for patients suffering from treatment-resistant schizophrenia.
Key Takeaways
- Newron Pharmaceuticals has secured up to EUR 38 million to advance its ENIGMA-TRS phase III program.
- The investment includes provisions for additional share subscriptions based on clinical study outcomes.
- Evenamide is positioned as a promising add-on therapy for patients with schizophrenia, showcasing a unique mechanism of action.
In conclusion, Newron Pharmaceuticals is poised for significant advancements in its clinical programs, bolstered by strategic financial support. As the company continues to explore the potential of evenamide, it may soon offer new hope for those grappling with treatment-resistant schizophrenia. The future of psychiatric therapy could be on the cusp of transformation.
Read more → www.pharmabiz.com